Selecting patients with HER2-low breast cancer: Getting out of the tangle
2022 · European Journal of Cancer · 43 citations
https://doi.org/10.1016/j.ejca.2022.08.022
X
Ximena Baez‐Navarro
Erasmus MC(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
202
Citations
6
h-index
6
i10-index
Ximena Baez‐Navarro is an academic researcher from Erasmus MC. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 6, co-authored 12 publications.
ORCID: 0000-0002-0037-8906Papers by this author
worksHER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort
2023 · Modern Pathology · 40 citations
https://doi.org/10.1016/j.modpat.2022.100087
HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
2024 · Pathology · 19 citations
https://doi.org/10.1016/j.pathol.2023.10.022
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
2024 · Breast Cancer Research · 10 citations
https://doi.org/10.1186/s13058-024-01783-z
HER2-low across solid tumours: different incidences and definitions
2025 · Pathology · 2 citations
https://doi.org/10.1016/j.pathol.2025.02.003
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat